Trinity Biotech (TRIB) received notice from the Nasdaq Stock Market LLC that the company is not in compliance with Nasdaq Listing Rule ...

With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Trinity Biotech plc (TRIB), a leading developer of diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market, has seen its stock price touch a 52-week low ...

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market.

Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...

Trinity Biotech ( (TRIB)) has shared an update ... industry with the acquisition of Waveform Technologies Inc. Its products target point-of-care and clinical laboratory markets and are distributed ...

StockNews.com cut shares of Trinity Biotech (NASDAQ:TRIB – Free Report) from a hold rating to a sell rating in a research report released on Thursday. Trinity Biotech Stock Up 1.6 % Shares of TRIB ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.